Premium
Screening for prostate carcinoma
Author(s) -
D'Amico Anthony V.
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.20854
Subject(s) - medicine , prostate carcinoma , prostate specific antigen , prostate , carcinoma , oncology , prostate cancer screening , gynecology , urology , cancer
To date, the use of prostate‐specific antigen (PSA) screening in the U.S. has translated into lower PSA failure rates and, perhaps, to lower rates of disease‐specific mortality in men with prostate carcinoma. However, this later point remains a hypothesis and will be proven right or wrong in short order based on upcoming results from randomized screening studies. See also pages 943–51.